Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Mar 21, 2009; 15(11): 1331-1338
Published online Mar 21, 2009. doi: 10.3748/wjg.15.1331
Published online Mar 21, 2009. doi: 10.3748/wjg.15.1331
Table 1 Frequencies of clinical manifestations related to the degree of histological severity
Normal mucosa (Marsh 0) n = 6 (%) | LE (Marsh I) n = 9 (%) | Atrophy (Marsh III) n = 6 (%) | Pvalue | |
Flatulence | 4 (66.7) | 6 (66.7) | 4 (66.7) | 1 |
Distension | 2 (33.4) | 7 (77.8) | 4 (66.7) | 0.282 |
Abdominal pain | 0 (0.0) | 6 (66.7) | 4 (66.7) | 0.029 |
Diarrhea | 1 (16.7) | 4 (44.5) | 4 (66.7) | 0.300 |
Asthenia | 2 (33.4) | 2 (22.3) | 4 (66.7) | 0.213 |
Anemia | 0 (0) | 0 (0) | 1 (16.7) | 0.571 |
Hypertransaminasemia | 1 (16.7) | 1 (11.9) | 2 (33.3) | 0.783 |
Table 2 Relationship between the values of VAS and degree of histological damage
Normal mucosa (Marsh 0) n = 6 | LE (Marsh I) n = 9 | Atrophy (Marsh III) n = 6 | Pvalue | |
Flatulence | 36.6 ± 12.0 (0-60) | 28.8 ± 8.2 (0-60) | 36.6 ± 14.7 (0-80) | 0.839 |
Distension | 6.67 ± 4.2 (0-20) | 28.8 ± 6.7 (0-60) | 50.0 ± 16.9 (0-100) | 0.035 |
Abdominal pain | 0.0 ± 0.0 (0-20) | 31.1 ± 10.0 (0-80) | 26.6 ± 9.8 (0-60) | 0.06 |
Diarrhea | 8.33 ± 8.3 (0-50) | 17.7 ± 9.1 (0-80) | 30.0 ± 12.3 (0-80) | 0.384 |
Asthenia | 10.0 ± 6.8 (0-40) | 11.1 ± 7.5 (0-60) | 50.0 ± 16.9 (0-100) | 0.031 |
Table 3 Follow-up of patients who adhered to GFD
At basal evaluation | After GFD | |||||||||
Clinical features | EmA | tTGA (U/mL) | Biopsy | IELs | Clinical features | EmA | tTGA (U/mL) | Biopsy | IELs | |
Case 1 female 47 years | Flatulence, distension, abdominal pain, diarrhea, asthenia, anemia, osteopenia | > 1/160 | 74 | Marsh IIIb | --- | Asthenia | Neg. | 3.3 | Marsh I | 35% |
Case 2 female 24 years | Flatulence | > 1/160 | 159 | Marsh IIIb | --- | No symptoms | Neg. | 1.9 | --- | --- |
Case 3 male 41 years | Flatulence, distension, abdominal pain, diarrhea, asthenia, hypertransaminasemia | > 1/160 | 63.4 | Marsh IIIc | --- | Asthenia, hypertransaminasemia | Neg. | 2.0 | Marsh I | 28% |
Case 4 female 32 years | Osteopenia | 1/80 | 8.5 | Marsh IIIa | --- | Osteopenia | Neg. | 0 | --- | --- |
Case 5 female 22 years | Distension, abdominal pain, diarrhea, asthenia, hypertransaminasemia, osteopenia | 1/10 | 4.34 | Marsh IIIb | --- | Distension, osteopenia | Neg. | 1.0 | Marsh I | 42% |
Case 6 female 42 years | Flatulence, distension, osteopenia | Neg. | 2.0 | Marsh I | 40% | Osteopenia | Neg. | 2.4 | Marsh 0 | 22% |
Case 7 male 41 years | Osteopenia | Neg. | 3.34 | Marsh I | 26% | No symptoms | Neg. | 1.24 | Marsh I | 26% |
Case 8 female 38 years | Flatulence, distension, abdominal pain | Neg. | 4.04 | Marsh I | 42% | Flatulence | Neg. | 2.0 | Marsh 0 | 17% |
Case 9 male 37 years | Distension, abdominal pain, diarrhea, osteopenia | Neg. | 3.20 | Marsh I | 26% | Abdominal pain, diarrhea, osteopenia | Neg. | 2.4 | Marsh I | 28% |
Case 10 male 32 years | Flatulence, distension, abdominal pain, diarrhea, asthenia, osteopenia | Neg. | 2.34 | Marsh I | 35% | Flatulence, distension, abdominal pain, diarrhea, asthenia, osteopenia | Neg. | 1 | Marsh 0 | 14% |
Table 4 Evolution of symptoms after 1 year of follow-up for those patients who adhered to a GFD (n = 10; 5 Marsh I, 5 Marsh III)
Basal (mean values of VAS) | After 1 year of GFD (mean values of VAS) | Pvalue | |
Flatulence | 28 ± 8.9 | 5 ± 3.4 | 0.028 |
Distension | 42 ± 10.9 | 7 ± 4.7 | 0.014 |
Abdominal pain | 28 ± 9.0 | 7 ± 5.1 | 0.007 |
Diarrhea | 24 ± 10.2 | 4 ± 2.6 | 0.063 |
Asthenia | 28 ± 12.3 | 12 ± 6.6 | 0.133 |
Table 5 Patients who accepted follow-up but did not adhere to GFD
At basal evaluation | Follow-up | |||||||||
Clinical features | EmA | tTGA (U/mL) | Biopsy | IELs | Clinical features | EmA | tTGA (U/mL) | Biopsy | IELs | |
Case 1 male 23 years | Flatulence, distension, abdominal pain, diarrhea, asthenia | 1/40 | 6.76 | Marsh IIIb | ---- | Flatulence, distension, abdominal pain, diarrhea, asthenia | Neg. | 1.70 | Not accepted | --- |
Case 2 male 63 years | Osteopenia | Neg. | 4.07 | Marsh I | 29% | Osteopenia | Neg. | 2.2 | Marsh I | 25% |
Case 3 male 24 years | Flatulence, distension, abdominal pain, diarrhea, asthenia | Neg. | 3.47 | Marsh I | 25% | Flatulence, distension, diarrhea, asthenia | Neg. | 1.0 | Not accepted | --- |
Case 4 female 66 years | Flatulence, distension, abdominal pain | Neg. | 5.60 | Marsh I | 35% | Diarrhea, abdominal pain, distension, flatulence | Neg. | 15 | Marsh IIIa | --- |
Case 5 male 45 years | Asthenia | Neg. | 2.68 | Marsh 0 | 5% | Asthenia | Neg. | 2.0 | Marsh I | 28% |
Case 6 male 47 years | Flatulence | Neg. | 3.95 | Marsh 0 | 22% | Flatulence | Neg. | 1.0 | Marsh 0 | 5% |
Case 7 male 36 years | Distension | Neg. | 2.78 | Marsh 0 | 20% | Distension, hypertransaminasemia | Neg. | 1.2 | Not accepted | --- |
Case 8 male 36 years | Flatulence | Neg. | 2.80 | Marsh 0 | 18% | Flatulence | Neg. | 1.0 | Not accepted | --- |
- Citation: Mariné M, Fernández-Bañares F, Alsina M, Farré C, Cortijo M, Santaolalla R, Salas A, Tomàs M, Abugattas E, Loras C, Ordás I, Viver JM, Esteve M. Impact of mass screening for gluten-sensitive enteropathy in working population. World J Gastroenterol 2009; 15(11): 1331-1338
- URL: https://www.wjgnet.com/1007-9327/full/v15/i11/1331.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.1331